Broad protective immune responses elicited by bacterium-like particle-based intranasal pneumococcal particle vaccine displaying PspA2 and PspA4 fragments

References

• Walker CL, Rudan I, Liu L, Nair H, Theodoratou E, Bhutta ZA, O’Brien KL, Campbell H, Black RE. Global burden of childhood pneumonia and diarrhoea. Lancet. 2013;381:1405–1416. doi:10.1016/S0140-6736(13)60222-6.
   PubMed Web of Science ®Google Scholar
• Chen K, Zhang X, Shan W, Zhao G, Zhang T. Serotype distribution of Streptococcus pneumoniae and potential impact of pneumococcal conjugate vaccines in China: A systematic review and meta-analysis. Hum Vaccin Immunother. 2018;14:1453–1463. doi:10.1080/21645515.2018.1435224.
   Web of Science ®Google Scholar
• Thorrington D, Andrews N, Stowe J, Miller E, van Hoek AJ. Elucidating the impact of the pneumococcal conjugate vaccine programme on pneumonia, sepsis and otitis media hospital admissions in England using a composite control. BMC Med. 2018;16:13. doi:10.1186/s12916-018-1004-z.
   PubMed Web of Science ®Google Scholar
• Akata K, Chang B, Yatera K, Kawanami T, Naito K, Noguchi S, Kido T, Mukae H. The distribution and annual changes in the Streptococcus pneumoniae serotypes in adult Japanese patients with pneumococcal pneumonia from 2011 to 2015. J Infect Chemother. 2017;23:301–306. doi:10.1016/j.jiac.2017.01.008.
   PubMed Web of Science ®Google Scholar
• Kim GL, Seon SH, Rhee DK. Pneumonia and Streptococcus pneumoniae vaccine. Arch Pharm Res. 2017;40:885–893. doi:10.1007/s12272-017-0933-y.
   PubMed Web of Science ®Google Scholar
• Wantuch PL, Avci FY. Current status and future directions of invasive pneumococcal diseases and prophylactic approaches to control them. Hum Vaccin Immunother. 2018:1–7. doi:10.1080/21645515.2018.1470726.
   PubMed Web of Science ®Google Scholar
• Zhou H, He J, Wu B, Che D. Cost-effectiveness analysis of routine 13-valent pneumococcal conjugate vaccinations in Chinese infants. Hum Vaccin Immunother. 2018;14:1444-1452. doi:10.1080/21645515.2018.1438794.
   Web of Science ®Google Scholar
• Croney CM, Coats MT, Nahm MH, Briles DE, Crain MJ. PspA family distribution, unlike capsular serotype, remains unaltered following introduction of the heptavalent pneumococcal conjugate vaccine. Clin Vaccine Immunol. 2012;19:891–896. doi:10.1128/CVI.05671-11.
   PubMed Web of Science ®Google Scholar
• Deng X, Church D, Vanderkooi OG, Low DE, Pillai DR. Streptococcus pneumoniae infection: a Canadian perspective. Expert Rev Anti Infect Ther. 2013;11:781–791. doi:10.1586/14787210.2013.814831.
   PubMed Web of Science ®Google Scholar
• Mera R, Miller LA, Fritsche TR, Jones RN. Serotype replacement and multiple resistance in Streptococcus pneumoniae after the introduction of the conjugate pneumococcal vaccine. Microb Drug Resist. 2008;14:101–107. doi:10.1089/mdr.2008.0782.
   PubMed Web of Science ®Google Scholar
• Darrieux M, Goulart C, Briles D, Leite LC. Current status and perspectives on protein-based pneumococcal vaccines. Crit Rev Microbiol. 2015;41:190–200. doi:10.3109/1040841X.2013.813902.
   PubMed Web of Science ®Google Scholar
• Moffitt KL, Malley R. Next generation pneumococcal vaccines. Curr Opin Immunol. 2011;23:407–413. doi:10.1016/j.coi.2011.04.002.
   PubMed Web of Science ®Google Scholar
• Tai SS. Streptococcus pneumoniae protein vaccine candidates: properties, activities and animal studies. Crit Rev Microbiol. 2006;32:139–153. doi:10.1080/10408410600822942.
   PubMed Web of Science ®Google Scholar
• Hollingshead SK, Becker R, Briles DE. Diversity of PspA: mosaic genes and evidence for past recombination in Streptococcus pneumoniae. Infect Immun. 2000;68:5889–5900.
   PubMed Web of Science ®Google Scholar
• Briles DE, Hollingshead SK, Swiatlo E, Brooks-Walter A, Szalai A, Virolainen A, McDaniel LS, Benton KA, White P, Prellner K, et al. PspA and PspC: their potential for use as pneumococcal vaccines. Microb Drug Resist. 1997;3:401–408. doi:10.1089/mdr.1997.3.401.
   PubMed Web of Science ®Google Scholar
• Nabors GS, Braun PA, Herrmann DJ, Heise ML, Pyle DJ, Gravenstein S, Schilling M, Ferguson LM, Hollingshead SK, Briles DE, et al. Immunization of healthy adults with a single recombinant pneumococcal surface protein A (PspA) variant stimulates broadly cross-reactive antibodies to heterologous PspA molecules. Vaccine. 2000;18:1743–1754.
   PubMed Web of Science ®Google Scholar
• Moreno AT, Oliveira ML, Ferreira DM, Ho PL, Darrieux M, Leite LC, Ferreira JMC, Pimenta FC, Andrade ALSS, Miyaji EN. Immunization of mice with single PspA fragments induces antibodies capable of mediating complement deposition on different pneumococcal strains and cross-protection. Clin Vaccine Immunol. 2010;17:439–446. doi:10.1128/CVI.00430-09.
   PubMed Web of Science ®Google Scholar
• Brandileone MC, Andrade AL, Teles EM, Zanella RC, Yara TI, Di Fabio JL, Hollingshead SK. Typing of pneumococcal surface protein A (PspA) in Streptococcus pneumoniae isolated during epidemiological surveillance in Brazil: towards novel pneumococcal protein vaccines. Vaccine. 2004;22:3890–3896. doi:10.1016/j.vaccine.2004.04.009.
   PubMed Web of Science ®Google Scholar
• Beall B, Gherardi G, Facklam RR, Hollingshead SK. Pneumococcal pspA sequence types of prevalent multiresistant pneumococcal strains in the United States and of internationally disseminated clones. 2000; 38:3663–3669.
   Google Scholar
• Hollingshead SK, Baril L, Ferro S, King J, Coan P, Briles DE. Pneumococcal surface protein A (PspA) family distribution among clinical isolates from adults over 50 years of age collected in seven countries. J Med Microbiol. 2006;55:215–221. doi:10.1099/jmm.0.46268-0.
   PubMed Web of Science ®Google Scholar
• Qian J, Yao K, Xue L, Xie G, Zheng Y, Wang C, Shang Y, Wang H, Wan L, Liu L, et al. Diversity of pneumococcal surface protein A (PspA) and relation to sequence typing in Streptococcus pneumoniae causing invasive disease in Chinese children. Eur J Clin Microbiol Infect Dis. 2012;31:217–223. doi:10.1007/s10096-011-1296-9.
   PubMed Web of Science ®Google Scholar
• Daniels CC, Briles TC, Mirza S, Hakansson AP, Briles DE. Capsule does not block antibody binding to PspA, a surface virulence protein of Streptococcus pneumoniae. Microb Pathog. 2006;40:228–233. doi:10.1016/j.micpath.2006.01.007.
   PubMed Web of Science ®Google Scholar
• Ferreira DM, Oliveira ML, Moreno AT, Ho PL, Briles DE, Miyaji EN. Protection against nasal colonization with Streptococcus pneumoniae by parenteral immunization with a DNA vaccine encoding PspA (Pneumococcal surface protein A). Microb Pathog. 2010;48:205–213. doi:10.1016/j.micpath.2010.02.009.
   PubMed Web of Science ®Google Scholar
• Briles DE, Hollingshead SK, Paton JC, Ades EW, Novak L, van Ginkel FW, Benjamin WH. Immunizations with pneumococcal surface protein A and pneumolysin are protective against pneumonia in a murine model of pulmonary infection with Streptococcus pneumoniae. J Infect Dis. 2003;188:339–348. doi:10.1086/376571.
   PubMed Web of Science ®Google Scholar
• Briles DE, Hollingshead SK, King J, Swift A, Braun PA, Park MK, Ferguson LM, Nahm MH, Nabors GS. Immunization of humans with recombinant pneumococcal surface protein A (rPspA) elicits antibodies that passively protect mice from fatal infection with Streptococcus pneumoniae bearing heterologous PspA. J Infect Dis. 2000;182:1694–1701. doi:10.1086/317602.
   PubMed Web of Science ®Google Scholar
• Goulart C, Darrieux M, Rodriguez D, Pimenta FC, Brandileone MC, de Andrade AL, Leite LCC. Selection of family 1 PspA molecules capable of inducing broad-ranging cross-reactivity by complement deposition and opsonophagocytosis by murine peritoneal cells. Vaccine. 2011;29:1634–1642. doi:10.1016/j.vaccine.2010.12.074.
   PubMed Web of Science ®Google Scholar
• Piao Z, Akeda Y, Takeuchi D, Ishii KJ, Ubukata K, Briles DE, Tomono K, Oishi K. Protective properties of a fusion pneumococcal surface protein A (PspA) vaccine against pneumococcal challenge by five different PspA clades in mice. Vaccine. 2014;32:5607–5613. doi:10.1016/j.vaccine.2014.07.108.
   PubMed Web of Science ®Google Scholar
• Lu J, Sun T, Wang D, Dong Y, Xu M, Hou H, Kong FT, Liang C, Gu T, Chen P, et al. Protective immune responses elicited by fusion protein containing PsaA and PspA fragments. Immunol Invest. 2015;44:482–496. doi:10.3109/08820139.2015.1037956.
   PubMed Web of Science ®Google Scholar
• Nguyen CT, Kim SY, Kim MS, Lee SE, Rhee JH. Intranasal immunization with recombinant PspA fused with a flagellin enhances cross-protective immunity against Streptococcus pneumoniae infection in mice. Vaccine. 2011;29:5731–5739. doi:10.1016/j.vaccine.2011.05.095.
   PubMed Web of Science ®Google Scholar
• Darrieux M, Moreno AT, Ferreira DM, Pimenta FC, de Andrade AL, Lopes AP, Leite LCC, Miyaji EN. Recognition of pneumococcal isolates by antisera raised against PspA fragments from different clades. J Med Microbiol. 2008;57:273–278. doi:10.1099/jmm.0.47661-0.
   PubMed Web of Science ®Google Scholar
• Darrieux M, Miyaji EN, Ferreira DM, Lopes LM, Lopes AP, Ren B, Briles DE, Hollingshead SK, Leite LCC. Fusion proteins containing family 1 and family 2 PspA fragments elicit protection against Streptococcus pneumoniae that correlates with antibody-mediated enhancement of complement deposition. Infect Immun. 2007;75:5930–5938. doi:10.1128/IAI.00940-07.
   PubMed Web of Science ®Google Scholar
• Xin W, Li Y, Mo H, Roland KL, Curtiss R 3rd. PspA family fusion proteins delivered by attenuated Salmonella enterica serovar Typhimurium extend and enhance protection against Streptococcus pneumoniae. Infect Immun. 2009;77:4518–4528. doi:10.1128/IAI.00486-09.
   PubMed Web of Science ®Google Scholar
• Lu J, Hou H, Wang D, Leenhouts K, Roosmalen MLV, Sun T, Gu T, Song Y, Jiang C, Kong W, et al. Systemic and mucosal immune responses elicited by intranasal immunization with a pneumococcal bacterium-like particle-based vaccine displaying pneumolysin mutant Plym2. Immunol Lett. 2017;187:41–46. doi:10.1016/j.imlet.2017.05.003.
   PubMed Web of Science ®Google Scholar
• Cutts FT, Zaman SMA, Enwere G, Jaffar S, Levine OS, Okoko JB, Oluwalana C, Vaughan A, Obaro SK, Leach A, et al. Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial. Lancet. 2005;365:1139–1146. doi:10.1016/S0140-6736(05)71876-6.
   PubMed Web of Science ®Google Scholar
• Neutra MR, Kozlowski PA. Mucosal vaccines: the promise and the challenge. Nat Rev Immunol. 2006;6:148–158. doi:10.1038/nri1777.
   PubMed Web of Science ®Google Scholar
• Srivastava A, Gowda DV, Madhunapantula SV, Shinde CG, Iyer M. Mucosal vaccines: a paradigm shift in the development of mucosal adjuvants and delivery vehicles. APMIS. 2015;123:275–288. doi:10.1111/apm.12351.
   PubMed Web of Science ®Google Scholar
• Van Braeckel-Budimir N, Haijema BJ, Leenhouts K. Bacterium-like particles for efficient immune stimulation of existing vaccines and new subunit vaccines in mucosal applications. Front Immunol. 2013;4:282. doi:10.3389/fimmu.2013.00282.
   PubMed Web of Science ®Google Scholar
• de Haan A, Haijema BJ, Voorn P, Meijerhof T, van Roosmalen ML, Leenhouts K. Bacterium-like particles supplemented with inactivated influenza antigen induce cross-protective influenza-specific antibody responses through intranasal administration. Vaccine. 2012;30:4884–4891. doi:10.1016/j.vaccine.2012.04.032.
   PubMed Web of Science ®Google Scholar
• Keijzer C, Haijema BJ, Meijerhof T, Voorn P, de Haan A, Leenhouts K, van Roosmalen ML, van Eden W, Broere F. Inactivated influenza vaccine adjuvanted with bacterium-like particles induce systemic and mucosal influenza A virus specific T-cell and B-cell responses after nasal administration in a TLR2 dependent fashion. Vaccine. 2014;32:2904–2910. doi:10.1016/j.vaccine.2014.02.019.
   PubMed Web of Science ®Google Scholar
• Saluja V, Amorij JP, van Roosmalen ML, Leenhouts K, Huckriede A, Hinrichs WL, Frijlink HW. Intranasal delivery of influenza subunit vaccine formulated with GEM particles as an adjuvant. Aaps J. 2010;12:109–116. doi:10.1208/s12248-009-9168-2.
   PubMed Web of Science ®Google Scholar
• Ramirez K, Ditamo Y, Rodriguez L, Picking WL, van Roosmalen ML, Leenhouts K, Pasetti MF. Neonatal mucosal immunization with a non-living, non-genetically modified Lactococcus lactis vaccine carrier induces systemic and local Th1-type immunity and protects against lethal bacterial infection. Mucosal Immunol. 2010;3:159–171. doi:10.1038/mi.2009.131.
   PubMed Web of Science ®Google Scholar
• Denoel P, Philipp MT, Doyle L, Martin D, Carletti G, Poolman JT. A protein-based pneumococcal vaccine protects rhesus macaques from pneumonia after experimental infection with Streptococcus pneumoniae. Vaccine. 2011;29:5495–5501. doi:10.1016/j.vaccine.2011.05.051.
   PubMed Web of Science ®Google Scholar
• Marriott HM, Mitchell TJ, Dockrell DH. Pneumolysin: a double-edged sword during the host-pathogen interaction. Curr Mol Med. 2008;8:497–509.
   PubMed Web of Science ®Google Scholar
• Lu J, Sun T, Hou H, Xu M, Gu T, Dong Y, Wang D, Chen P, Wu C, Liang C, et al. Detoxified pneumolysin derivative Plym2 directly protects against pneumococcal infection via induction of inflammatory cytokines. Immunol Invest. 2014;43:717–726. doi:10.3109/08820139.2014.930478.
   PubMed Web of Science ®Google Scholar
• van Roosmalen ML, Kanninga R, El Khattabi M, Neef J, Audouy S, Bosma T, Kuipers A, Post E, Steen A, Kok J, et al. Mucosal vaccine delivery of antigens tightly bound to an adjuvant particle made from food-grade bacteria. Methods. 2006;38:144–149. doi:10.1016/j.ymeth.2005.09.015.
   PubMed Web of Science ®Google Scholar